Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am Heart J. 2014 May;167(5):683-9. doi: 10.1016/j.ahj.2014.01.014. Epub 2014 Feb 26.

Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.

Author information

  • 1Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA.
  • 2Department of Medicine, Section of Cardiovascular Medicine; Yale University School of Medicine, Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT; Department of Epidemiology and Public Health, Section of Health Policy and Administration, New Haven, CT; Robert Wood Johnson Clinical Scholars Program, New Haven, CT.
  • 3Institute for Clinical Evaluative Sciences, Toronto, Canada; Department of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto, Canada; Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
  • 4Yale University School of Medicine, Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT; Department of Medicine, Section of General Internal Medicine, New Haven, CT.
  • 5Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA; Institute for Clinical Evaluative Sciences, Toronto, Canada; Department of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto, Canada; University Health Network, Toronto, Canada. Electronic address: cjackevicius@westernu.edu.

Abstract

BACKGROUND:

We previously found that the use of ezetimibe increased rapidly with different patterns between the United States (US) and Canada prior to the landmark Ezetimibe and Simvastatin in Hypercholesterolemia Enhance Atherosclerosis Regression (ENHANCE) trial, which was reported in January 2008, and failed to show that the drug slowed the progression of atherosclerosis. What is not known is how practice in the 2 countries changed after the ENHANCE trial. We examined ezetimibe use trends in the US and Canada before and after the reporting of the ENHANCE trial.

METHODS:

We conducted a population-based, retrospective, time-series analysis using the data collected by IMS Health in the US and CompuScript in Canada from January 1, 2002, to December 31, 2009. The main outcome measure was monthly number of prescriptions for ezetimibe-containing products.

RESULTS:

The monthly number of ezetimibe prescriptions/100,000 population rose from 6 to 1,082 in the US from November 2002 to January 2008, then significantly declined to 572/100,000 population by December 2009 after the release of the ENHANCE trial, a decrease of 47.1% (P < .001). In contrast, in Canada, use continuously rose from 2 to 495/100,000 population from June 2003 to December 2009 (P = .2). United States expenditures totaled $2.24 billion in 2009.

CONCLUSIONS:

Ezetimibe remains commonly used in both the US and Canada. Ezetimibe use has decreased in the US post-ENHANCE, whereas use has gradually but steadily increased in Canada. The diverging patterns of ezetimibe use in the US and Canada require further investigation, as they reveal that a common evidence base is eliciting very different utilization patterns in neighboring countries.

Copyright © 2014 Mosby, Inc. All rights reserved.

PMID:
24766978
[PubMed - indexed for MEDLINE]
PMCID:
PMC4215424
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk